Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics

  • Iris Maurer
  • Hans-Jürgen Möller
Part of the Developments in Molecular and Cellular Biochemistry book series (DMCB, volume 21)


There is increasing evidence that a defect of the mitochondrial respiratory chain is implicated in the development of Parkinson disease. Decreased complex I activity of the mitochondrial respiratory chain has been reported in platelets, muscle, and brain of patients with Parkinson disease. Extrapyramidal symptoms (e.g. parkinsonism and dystonic reactions) are major limiting side effects of neuroleptics. Experimental evidence suggests that neuroleptics inhibit complex I in rat brain. There has not been a study of the effects of neuroleptics in human tissue, however. We therefore analyzed the activities of complexes I + III, complexes II + III, succinate dehydrogenase, complex IV (cytochrome c oxidase), and of citrate synthase in normal human brain cortex after the addition of haloperidol and chlorpromazine and the atypical neuroleptics risperidone, zotepine, and clozapine. Activity of complex I was progressively inhibited by all neuroleptics. Half-maximal inhibition (IC50) was 0.1 mM for haloperidol, 0.4 mM for chlorpromazine, and 0.5 mM for risperidone and zotepine. Clozapine had no effect on enzyme activity at concentrations up to 0.5 mM, followed by a slow decline with a maximum inhibition of 70% at 10 mM. IC50 was at about 2.5 mM. Thus, the concentration of clozapine needed to cause 50% inhibition of the activity of complexes I and III was about 5 times that of zotepine and risperidone, about 6 times that of chlorpromazine, and 25 times that of haloperidol. The inhibition thus paralleled the incidence of extrapyramidal effects caused by the different neuroleptics as they are known from numerous clinical studies. Our data support the hypothesis that neuroleptic-induced extrapyramidal side effects may be due to inhibition of the mitochondrial respiratory chain. (Mol Cell Biochem 174: 255–259, 1997)

Key words

mitochondria neuroleptics oxidative phosphorylation complex I 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Baron JC, Martinot JL, Cambon H et al: Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacol 99: 463–472, 1989CrossRefGoogle Scholar
  2. 2.
    Schapira AHV: Evidence for mitochondrial dysfunction in Parkinson’s disease — a critical appraisal. Mov Disord 9: 125–138, 1994PubMedCrossRefGoogle Scholar
  3. 3.
    Parker WD, Boyson S J, Parks JK: Abnormalities of the electron transport chain in idiopathic Parkinson’s disease. Ann Neurol 26: 719–723, 1989PubMedCrossRefGoogle Scholar
  4. 4.
    Shoffner JM, Watts RL, Juncos JL, Torroni A, Wallace DC: Mitochondrial oxidative phosphorylation defects in Parkinson’s disease. Ann Neurol 30: 332–339, 1991PubMedCrossRefGoogle Scholar
  5. 5.
    Ramsay RR, Dadgar J, Trevor A, Singer TP: Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neu-rotoxicity of MPTP. Life Sci 39: 581–588, 1986PubMedCrossRefGoogle Scholar
  6. 6.
    Subramanyam B, Rollema H, Woolf T, Castagnoli N: Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats. Biochem Biophys Res Commun 166: 238–244, 1990PubMedCrossRefGoogle Scholar
  7. 7.
    Burkhardt C, Kelly JP, Lim Y-H, Filley CM, Parker WD: Neuroleptic medications inhibit complex I of the electron transport chain. Ann Neurol 33: 512–517, 1993PubMedCrossRefGoogle Scholar
  8. 8.
    Jackson Lewis V, Przedborski S, Jiang H, Fahn S: Effect of neuroleptics on the mitochondrial electron transport chain [abstract]. Soc Neurosci Abstr 18: 1103, 1992Google Scholar
  9. 9.
    Nicklas WJ, Vyas I, Heikkila RE: Inhibition of NADH-linked oxidation in brain mitochondria by MPP+, a metabolite of the neurotoxin MPTP. Life Sci 36: 2503–2508, 1985PubMedCrossRefGoogle Scholar
  10. 10.
    Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the folin reagent. J Biol Chem 193: 265–275, 1951PubMedGoogle Scholar
  11. 11.
    Casey DE: Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacol 99: S47–S53, 1989CrossRefGoogle Scholar
  12. 12.
    Matsuda LA, Schmidt CJ, Hanson GR, Gibb JW: Effect of 1-methyl-4-phenyl-l, 2, 3, 6-tetrahydropyridine (MPTP) on striatal tyrosine hydroxylase and tryptophan hydroxylase in rat. Neuropharmacology 25: 249–255, 1986PubMedCrossRefGoogle Scholar
  13. 13.
    Wase AW, Christensen J, Polley E: The accumulation of S35-chlor-promazine in brain. Arch Neurol Psychiat 75: 54–56, 1995CrossRefGoogle Scholar
  14. 14.
    Sjöstrand SE, Cassano GB, Hansson E: The distribution of 35S-chlor-promazine in mice studied by whole body autoradiography. Arch Int Pharmacodyn 156: 34–46, 1965PubMedGoogle Scholar
  15. 15.
    Lindquist NG: Accumulation in vitro of 35S-chlorpromazine in the neuromelanin of human substantia nigra and locus coeruleus. Arch Int Pharmacodyn 200: 190–195, 1972PubMedGoogle Scholar
  16. 16.
    Sunderland T, Cohen BM: Blood to brain distribution of neuroleptics. Psychiatr Res 20: 299–305, 1987CrossRefGoogle Scholar
  17. 17.
    Noda K, Suzuki A, Okui M, Noguchi H, Nishiura M, Nishiura N: Pharmacokinetics and metabolism of 2-chloro-l l-(2-dimethyl-aminoethoxy)-dibenzothiepine (zotepine) in rat, mouse, dog and man. Drug Res 29: 1595–1600, 1979Google Scholar
  18. 18.
    Burt DR, Creese I, Snyder SH: Antischizophrenic drugs: chronic treatment elevates dopamine binding in brain. Science 196: 326–328, 1977PubMedCrossRefGoogle Scholar
  19. 19.
    Costall B, Fortune DH, Naylor RJ, Marsden CD, Pycock C: Serotoninergic involvement with neuroleptic catalepsy. Neuropharmacology 14: 859–868, 1975PubMedCrossRefGoogle Scholar
  20. 20.
    Przedborski S, Jackson-Lewis V, Muthane U et al.: Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity. Ann Neurol 34: 715–723, 1993PubMedCrossRefGoogle Scholar
  21. 21.
    Nielsen EB, Lyon M: Evidence for cell loss in corpus striatum after long-term treatment with a neuroleptic drug (flupenthixol) in rats. Psychopharmacology 59: 85–89, 1978PubMedCrossRefGoogle Scholar
  22. 22.
    Fibiger HC, Lloyd KG: Is the dopamine hypothesis of tardive dyskinesia completely wrong? Trends Neuro Sci 9: 259–260, 1986CrossRefGoogle Scholar
  23. 23.
    Linnane AW, Marzuki S, Ozawa T, Tanaka M: Mitochondrial DNA mutations as an important contributor to ageing and degenerative diseases. Lancet 3: 642–645, 1989CrossRefGoogle Scholar
  24. 24.
    Wallace DC: Mitochondrial genetics: A paradigm for ageing and degenerative diseases? Science 256: 628–632, 1992PubMedCrossRefGoogle Scholar
  25. 25.
    Corral-Debrinski M, Horton T, Lott MT, Shoffner JM, Beal MF, Wallace DC: Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age. 13 Nature Genet 2: 324–329, 1992CrossRefGoogle Scholar
  26. 26.
    Soong NW, Hinton DR, Cortopassi G, Arnheim N: Mosaicism for a specific somatic mitochondrial DNA mutation in adult human brain. Nature Genet 2: 318–323, 1992PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1997

Authors and Affiliations

  • Iris Maurer
    • 1
  • Hans-Jürgen Möller
    • 2
  1. 1.Department of NeurologyFriedrich-Wilhelms-UniversitätBonnGermany
  2. 2.Department of PsychiatryLudwig-Maximilians-UniversitätMünchenGermany

Personalised recommendations